Analysis commissioned by Pepdor · performed by an independent contract laboratory
coa@pepdor.com · pepdor.com/ledger
CERTIFICATE OF ANALYSIS - Semaglutide batch SM-2606-C
pepdor.com/batch/sm-2606-c
How to read this certificate
This document records the release testing for Semaglutide batch SM-2606-C, issued Jun 08, 2026. The headline figure is the reversed-phase HPLC purity of 99.3%, read by UV absorbance at 220 nm - the wavelength where the peptide bond absorbs - so it reflects how much of the sample is intact Semaglutide rather than truncated sequences, deletion products, or process residuals.
Identity is a separate question from purity, so it is confirmed on its own by electrospray mass spectrometry (ESI-MS), which checks the measured mass against the theoretical mass of the peptide. Bacterial endotoxin is measured by the LAL assay and sterility by direct culture. Where a row above reads "Not tested", that parameter was outside the scope of this batch and Pepdor makes no claim about it - nothing here is inferred or carried over from an earlier lot.
Every result traces back to a physical sample pulled from the filled lot, not a hand-picked vial. You can cross-check this certificate against the full batch record for SM-2606-C and any independent third-party reports for this batch, all published unedited in the public Test Ledger. If you have sent a vial of this batch to your own lab, you can add that report too - the ledger is append-only.